ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc., announced this morning that it has executed a Material Transfer Agreement (MTA) with Archimedes Development Limited. This collaboration enables the companies to identify possible synergies between their technology platforms.
“Multiple studies in different model systems have shown that Homspera can protect experimental animals and enhance their immune responses to vaccine-delivered antigens, DNA-encoded viral proteins or tumor antigens, as well as provide protection in our anthrax and influenza therapeutic studies,” stated Hal Siegel, Ph.D., ImmuneRegen’s Vice President and Chief Scientific Officer.
He continued, “In addition to these findings in animals where Homspera has been administered intranasally as a liquid, inhaled or injected under the skin, we have shown in laboratory studies that Homspera can stimulate blood-forming stem cells to produce more white blood cell precursors, particularly those for granulocytes and macrophages, mature blood cells which play a significant role in immune responses. The ability to administer Homspera intranasally is one we are particularly interested in pursuing. Mucosal vaccination may be more efficacious than injected vaccines for diseases like influenza, intestinal diseases and HIV/AIDS. At times, such as pandemic influenza treatment or vaccination, intranasal administration might be desirable.”
Alan Smith, Ph.D., Archimedes’ Vice President of Research & Development, commented, “We recognize the growing need to improve the efficacy of available antigens and to facilitate mass vaccination by means of innovative approaches such as mucosal administration. As a recognized leader in this field we are excited to be collaborating with ImmuneRegen to apply our world-leading expertise and technology platforms to the intranasal delivery of Homspera.”